Nippon Chemiphar Co., Ltd.

Tokyo Stock Exchange 4539.T

Nippon Chemiphar Co., Ltd. Price to Earnings Ratio (P/E) on January 14, 2025: -28.80

Nippon Chemiphar Co., Ltd. Price to Earnings Ratio (P/E) is -28.80 on January 14, 2025, a -283.70% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.
  • Nippon Chemiphar Co., Ltd. 52-week high Price to Earnings Ratio (P/E) is 15.89 on March 27, 2024, which is 155.20% above the current Price to Earnings Ratio (P/E).
  • Nippon Chemiphar Co., Ltd. 52-week low Price to Earnings Ratio (P/E) is -4,630.10 on December 20, 2024, which is -15,979.38% below the current Price to Earnings Ratio (P/E).
  • Nippon Chemiphar Co., Ltd. average Price to Earnings Ratio (P/E) for the last 52 weeks is -40.16.
Key data
Date Price to Earnings Ratio (P/E) Price to Sales Ratio (P/S) Price to Book Ratio (P/B) Dividend Yield
Market news
Loading...
Tokyo Stock Exchange: 4539.T

Nippon Chemiphar Co., Ltd.

CEO Mr. Kazushiro Yamaguchi
IPO Date Jan. 1, 2001
Location Japan
Headquarters 2-2-3, Iwamoto-cho
Employees 887
Sector Health Care
Industries
Description

Nippon Chemiphar Co., Ltd., together with its subsidiaries, manufactures, markets, imports, exports, and sells, ethical pharmaceuticals and diagnostic agents in Japan and internationally. It offers diagnostic products, such as IgE NC, a diagnostic kit that provides results and reveals total IgE levels, as well as 57 individual allergen reagents; and DP3000, a device for allergen-specific IgE measurements. The company also develops NC-2400, a PPAR-delta agonist; NC-2500, a novel advanced xanthine oxidoreductase inhibitor for the treatment of hyperuricemia/gout; and NC-2600, a P2X4 receptor antagonist for the treatment of neuropathic pain. In addition, it develops NC-2700, a novel urate transporter 1 inhibitor that enhance excretion urate to urine; NC-2800, a delta opioid receptor agonist for the treatment of depression/anxiety; Uralyt-U, an alkalization therapeutic drug; Soleton, an analgesic and anti-inflammatory drug; and Calvan, a hypertension therapeutic drug. Further, the company provides quasi-drugs, nutrients, health foods, cosmetics, and various type of creams. It distributes its generic pharmaceuticals through wholesalers to hospitals and pharmacies. The company was formerly known as Hitachi Chemical Co., Ltd. and changed its name to Nippon Chemiphar Co., Ltd. in 1970. Nippon Chemiphar Co., Ltd. was founded in 1950 and is headquartered in Tokyo, Japan.

Similar companies

4521.T

Kaken Pharmaceutical Co., Ltd.

USD 26.94

-0.58%

4553.T

Towa Pharmaceutical Co., Ltd.

USD 20.75

-0.79%

4506.T

Sumitomo Pharma Co., Ltd.

USD 3.49

1.85%

4516.T

Nippon Shinyaku Co., Ltd.

USD 24.53

-2.23%

StockViz Staff

January 15, 2025

Any question? Send us an email